Strides Arcolab Ltd (STAR.NS)
20 Oct 2014
|Market Cap (Mil.):||Rs38,681.91|
|Shares Outstanding (Mil.):||59.57|
MUMBAI - Strides Arcolab Ltd has agreed to buy smaller rival Shasun Pharmaceuticals Ltd in an all-stock deal, valued at about $200 million, to bolster its generic medicine and drug ingredient businesses.
* Deal valued at about $200 mln based on Friday closing price
MUMBAI, Sept 29 - Indian generic drugmaker Strides Arcolab Ltd said on Monday it had agreed to merge with smaller peer Shasun Pharmaceuticals Ltd in an all-stock deal.
* NSE ends 0.21 pct higher; BSE index gains 0.04 pct * Crompton Greaves jumps on demerger proposal * Mahindra and Mahindra slumps after block deals * Strides Arcolab gains; Mankekar raises stake to 4.7 pct By Abhishek Vishnoi MUMBAI, July 17 - Indian shares rose for a third straight session on Thursday as lenders such as Kotak Mahindra Bank extended gains on upbeat sentiment as the central bank exempted long-term bonds for the infrastructure sector from reserve req
(Corrects typo in company name to Strides from Stride in headline) * Shares in India's Strides Arcolab Ltd gain 2 percent after investor Shivanand Shankar Mankekar raised his stake in the company to 4.7 percent in the June quarter from 1.26 percent held earlier, according to exchange data. * Mankekar increased his share holding in the company via three entities namely, Laxmi Shivanand Mankekar, Shivanand Shankar Mankekar and Kedar Shivanand Mankekar. * Private investor Mankekar is a known stock
Reuters Market Eye - Strides Arcolab surges 6.3 percent after the drugmaker said on Friday its oral drug manufacturing facility in Bangalore continues to maintain compliance with the manufacturing standards of the U.S. health regulator.
* India's Strides Arcolab Ltd surges 6.3 percent after the drugmaker said on Friday its oral drug manufacturing facility in Bangalore continues to maintain compliance with the manufacturing standards of the U.S. health regulator. * "U.S. FDA recently inspected this facility as part of GMP compliance audit and raised Form 483 (inspection observations) during the Dec 2013 inspection (which has now been satisfactorily closed)," Macquarie said in a note to its clients. * This is a key positive dev